发布求助
文献互助 智能选刊 最新文献

Internal Medicine最新文献

筛选
英文 中文
Postictal Thoracocervicofacial Purpura. 后胸颈面紫癜。
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-26 DOI: 10.2169/internalmedicine.5372-25
Kimitaka Katanazaka, Kazuma Koda, Kenji Sekiguchi, Tatsuo Matsushita
{"title":"Postictal Thoracocervicofacial Purpura.","authors":"Kimitaka Katanazaka, Kazuma Koda, Kenji Sekiguchi, Tatsuo Matsushita","doi":"10.2169/internalmedicine.5372-25","DOIUrl":"10.2169/internalmedicine.5372-25","url":null,"abstract":"","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3175"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metachronous Occurrence of Mucosa-associated Lymphoid Tissue (MALT) Lymphoma in the Esophagus and Tonsillar Diffuse Large B-cell Lymphoma 18 Years After Helicobacter pylori Eradication for Gastric MALT Lymphoma. 胃粘膜相关淋巴组织（MALT）淋巴瘤幽门螺杆菌根除18年后食道和扁桃体弥漫性大b细胞淋巴瘤异时发生1例
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-26 DOI: 10.2169/internalmedicine.5265-25
Hourin Cho, Eri Iwata, Ryota Niikura, Mariko Hamada, Yoshika Akimoto, Naoyoshi Nagata, Akihiko Gotoh, Jun Matsubayashi, Naoya Nakamura, Kiyoaki Tsukahara, Takao Itoi, Koichiro Abe, Takashi Kawai
{"title":"Metachronous Occurrence of Mucosa-associated Lymphoid Tissue (MALT) Lymphoma in the Esophagus and Tonsillar Diffuse Large B-cell Lymphoma 18 Years After Helicobacter pylori Eradication for Gastric MALT Lymphoma.","authors":"Hourin Cho, Eri Iwata, Ryota Niikura, Mariko Hamada, Yoshika Akimoto, Naoyoshi Nagata, Akihiko Gotoh, Jun Matsubayashi, Naoya Nakamura, Kiyoaki Tsukahara, Takao Itoi, Koichiro Abe, Takashi Kawai","doi":"10.2169/internalmedicine.5265-25","DOIUrl":"10.2169/internalmedicine.5265-25","url":null,"abstract":"<p><p>A 51-year-old man was diagnosed with gastric mucosa-associated lymphoid tissue (MALT) lymphoma after presenting with fold convergence on upper gastrointestinal radiography and nausea. He tested positive for Helicobacter pylori, and eradication therapy decreased the size of the gastric MALT lymphoma. Eighteen years later, whitish subepithelial lesions were discovered in the middle thoracic esophagus which were diagnosed to be esophageal MALT lymphoma. Six months later, the left tonsillar swelling was identified as diffuse large B-cell lymphoma (DLBCL). Complete remission was achieved after treatment with rituximab and chemotherapy. To our knowledge, this is the first reported case of metachronous gastric and esophageal MALT lymphoma with tonsillar DLBCL.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3111-3116"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Myeloid Leukemia with MYC Amplification on a Ring Chromosome 8. 8号染色体环上MYC扩增的急性髓系白血病。
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-19 DOI: 10.2169/internalmedicine.5171-24
Yuta Baba, Hirotaka Sakai, Nodoka Maeda, Maasa Abe, Nobuyuki Kabasawa, Tetsuya Fukuda
{"title":"Acute Myeloid Leukemia with MYC Amplification on a Ring Chromosome 8.","authors":"Yuta Baba, Hirotaka Sakai, Nodoka Maeda, Maasa Abe, Nobuyuki Kabasawa, Tetsuya Fukuda","doi":"10.2169/internalmedicine.5171-24","DOIUrl":"10.2169/internalmedicine.5171-24","url":null,"abstract":"<p><p>MYC amplification and overexpression are uncommon in acute myeloid leukemia (AML). An 82-year-old man developed leukocytosis during monoclonal gammopathy of renal significance. A chromosomal analysis revealed 46,XY,+r(8)[20]. Amplified MYC signals were detected on chromosome 8. The patient was diagnosed with AML and administered venetoclax and azacitidine. After the third course, clones with ring chromosome 8 had decreased in number, but clones unrelated to t(8;21)(q22;q22) had subsequently emerged. After the sixth course, the white blood cell count had markedly increased, and a chromosome analysis showed replacement of ring chromosome 8 with 46,XY,t(8;21)[20]. This case highlights the role of MYC amplification and overexpression in AML and suggests that BCL2 inhibition is a potential treatment.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3135-3139"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Auto Immune Glial Fibrillary Acidic Protein Astrocytopathy Coexistent with Positivity for Anti-NH2-terminal of α-enolase Antibodies. 自身免疫胶质纤维酸性蛋白星形细胞病伴α-烯醇化酶抗体抗nh2端阳性1例
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-26 DOI: 10.2169/internalmedicine.5528-25
Junichi Matsuo, Satoshi Namitome, Yasuyuki Hara, Tadashi Terasaki, Makoto Nakajima, Mitsuharu Ueda
{"title":"Auto Immune Glial Fibrillary Acidic Protein Astrocytopathy Coexistent with Positivity for Anti-NH<sub>2</sub>-terminal of α-enolase Antibodies.","authors":"Junichi Matsuo, Satoshi Namitome, Yasuyuki Hara, Tadashi Terasaki, Makoto Nakajima, Mitsuharu Ueda","doi":"10.2169/internalmedicine.5528-25","DOIUrl":"10.2169/internalmedicine.5528-25","url":null,"abstract":"<p><p>A 46-year-old woman presented with acute disturbance of consciousness, ataxia, and urinary retention. Although Hashimoto's encephalopathy was initially suspected due to the detection of serum anti-NH<sub>2</sub>-terminal α-enolase (NAE) antibodies, glial fibrillary acidic protein (GFAP)-astrocytopathy was also considered probable due to urinary retention. An additional examination revealed positive results for both anti-GFAP and anti-NAE antibodies. This case highlights the importance of considering antibodies to be examined based on clinical features, even in the presence of antibodies.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3150-3154"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded. 在接受派姆单抗治疗的患者中，必须排除对脑垂体、心脏和肾脏的不良反应。
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-26 DOI: 10.2169/internalmedicine.5463-25
Josef Finsterer
{"title":"In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded.","authors":"Josef Finsterer","doi":"10.2169/internalmedicine.5463-25","DOIUrl":"10.2169/internalmedicine.5463-25","url":null,"abstract":"","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3176"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Letter to the Editor: "In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded". 致编辑的回复：“在接受派姆单抗治疗的患者中，必须排除对脑垂体、心脏和肾脏的不良反应”。
IF 1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-26 DOI: 10.2169/internalmedicine.5568-25
Saori Inoue
{"title":"Response to Letter to the Editor: \"In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded\".","authors":"Saori Inoue","doi":"10.2169/internalmedicine.5568-25","DOIUrl":"10.2169/internalmedicine.5568-25","url":null,"abstract":"","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3177"},"PeriodicalIF":1.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Combined Dabrafenib and Trametinib Therapy in BRAFV600E Mutant Intrahepatic Cholangiocarcinoma with a Neurofibromatosis Type 2 Mutation. 病例报告：达非尼联合曲美替尼治疗BRAF V600E突变型肝内胆管癌合并2型突变神经纤维瘤病的疗效
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-26 DOI: 10.2169/internalmedicine.5141-24
Jumpei Yoshida, Keiji Sugiyama, Seira Owaki, Takumi Ito, Yuhei Yamaguchi, Ryosuke Emi, Yuki Sako, Mariko Satoh, Riku Ino, Kyoko Kato, Kazuhiro Shiraishi, Masaaki Shimada, Hiroyoshi Hattori, Chiyoe Kitagawa
{"title":"Efficacy of Combined Dabrafenib and Trametinib Therapy in BRAFV600E Mutant Intrahepatic Cholangiocarcinoma with a Neurofibromatosis Type 2 Mutation.","authors":"Jumpei Yoshida, Keiji Sugiyama, Seira Owaki, Takumi Ito, Yuhei Yamaguchi, Ryosuke Emi, Yuki Sako, Mariko Satoh, Riku Ino, Kyoko Kato, Kazuhiro Shiraishi, Masaaki Shimada, Hiroyoshi Hattori, Chiyoe Kitagawa","doi":"10.2169/internalmedicine.5141-24","DOIUrl":"10.2169/internalmedicine.5141-24","url":null,"abstract":"<p><p>We herein report a 41-year-old woman with BRAFV600E-mutated intrahepatic cholangiocarcinoma and a concurrent loss of function in NF2. The patient had a large liver tumor, multiple lymph nodes, and metastases to the lungs and pleura. She underwent six cycles of gemcitabine, cisplatin, and durvalumab but was refractory to this treatment. Comprehensive genomic profiling revealed a BRAFV600E mutation along with a loss of function in NF2. The patient was treated with a combination of oral dabrafenib and trametinib therapy. After two months, imaging showed reduced pleural effusion, tumor shrinkage, symptom resolution, and improved performance status, without significant side effects.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3107-3110"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Importance of Optimal Medical Therapy on the Clinical Outcomes of Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention. 最佳药物治疗对急性心肌梗死患者经皮冠状动脉介入治疗后临床预后的临床意义
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-19 DOI: 10.2169/internalmedicine.5192-24
Hirokazu Shimono, Akihiro Tokushige, Daisuke Kanda, Ryo Arikawa, Hideki Okui, Naoya Oketani, Mitsuru Ohishi
{"title":"Clinical Importance of Optimal Medical Therapy on the Clinical Outcomes of Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention.","authors":"Hirokazu Shimono, Akihiro Tokushige, Daisuke Kanda, Ryo Arikawa, Hideki Okui, Naoya Oketani, Mitsuru Ohishi","doi":"10.2169/internalmedicine.5192-24","DOIUrl":"10.2169/internalmedicine.5192-24","url":null,"abstract":"<p><p>Objective Optimal medical therapy (OMT) is recommended for the secondary prevention of acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). We investigated the relationship between the OMT prescription rate at hospital discharge and clinical outcomes in patients with AMI who underwent successful PCI. Methods We enrolled 294 consecutive AMI patients who underwent successful emergency PCI between January 2017 and December 2020. The patients were divided into two groups based on their medications at discharge: OMT, defined as a combination of statins, beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; and non-OMT, defined as the absence of at least one of the aforementioned agents. The primary outcome measure was major adverse cardiovascular events (MACEs), defined as the composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and heart failure requiring hospitalization. Results According to prescription data, 186 patients (63.3%) were prescribed OMT at discharge. During a median follow-up period of 957 (591-1,308) days, 45 patients developed MACEs. Kaplan-Meier curves showed a significantly lower incidence of MACE in the OMT group than in the non-OMT group (log-rank p<0.001). In the multivariate analysis, OMT remained independently associated with a reduced risk of MACE (hazard ratio, 0.47; 95% confidence interval: 0.25-0.88; p=0.017). Conclusion Fundamental OMT at discharge was associated with a reduced risk of MACE in AMI patients after successful PCI. Therefore, OMT may be necessary to improve the clinical outcomes of patients with AMI after discharge.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3088-3102"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Refractory TAFRO Syndrome with Cyclophosphamide: A Report of Two Cases. 环磷酰胺成功治疗难治性TAFRO综合征2例报告。
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-04-19 DOI: 10.2169/internalmedicine.4884-24
Kaito Nakamura, Kosuke Miki, Satoshi Ota, Tetsuya Hoshi
{"title":"Successful Treatment of Refractory TAFRO Syndrome with Cyclophosphamide: A Report of Two Cases.","authors":"Kaito Nakamura, Kosuke Miki, Satoshi Ota, Tetsuya Hoshi","doi":"10.2169/internalmedicine.4884-24","DOIUrl":"10.2169/internalmedicine.4884-24","url":null,"abstract":"<p><p>TAFRO syndrome is a rare, severe, and sometimes refractory condition characterized by thrombocytopenia, anasarca, a fever, reticulin myelofibrosis, and organomegaly. Although several treatment options have been proposed for this condition, there are few reported cases in the literature on successful treatment using cyclophosphamide in patients with TAFRO syndrome. We herein report two cases of refractory TAFRO syndrome successfully treated with intravenous cyclophosphamide. In both cases, after the initial treatment with high-dose glucocorticoids and tocilizumab failed, the administration of intravenous cyclophosphamide led to significant improvement. These cases suggest that intravenous cyclophosphamide may be a viable therapeutic option for refractory TAFRO syndromes.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3130-3134"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arrhythmias in Cronkhite-Canada Syndrome. cronkite - canada综合征中的心律失常。
IF 1.1 4区 医学
Internal Medicine Pub Date : 2025-11-01 Epub Date: 2025-05-15 DOI: 10.2169/internalmedicine.4834-24
Ryuzo Deguchi, Takashi Ueda, Masaya Sano, Hirohiko Sato, Erika Teramura, Jin Imai, Mia Fujisawa, Kota Tsuruya, Yoshitaka Arase, Tatehiro Kagawa
{"title":"Arrhythmias in Cronkhite-Canada Syndrome.","authors":"Ryuzo Deguchi, Takashi Ueda, Masaya Sano, Hirohiko Sato, Erika Teramura, Jin Imai, Mia Fujisawa, Kota Tsuruya, Yoshitaka Arase, Tatehiro Kagawa","doi":"10.2169/internalmedicine.4834-24","DOIUrl":"10.2169/internalmedicine.4834-24","url":null,"abstract":"<p><p>A 69-year-old man underwent upper and lower gastrointestinal endoscopic examinations for a detailed evaluation of diarrhea that had persisted for several months, which revealed multiple polyposis in the stomach, duodenum, colon, and terminal ileum. The histopathological findings also led to a diagnosis of Cronkhite-Canada syndrome (CCS). On admission, the patient had hypoalbuminemia and electrolyte abnormalities, including hypokalemia, and developed paroxysmal atrial fibrillation (Paf), although there were no apparent organic lesions in the heart. The patient's sinus rhythm was restored by electrical cardioversion, steroid therapy for CCS improved diarrhea symptoms and endoscopic findings, and the electrocardiogram findings were normal.</p>","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":"3117-3121"},"PeriodicalIF":1.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书